Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease

21 Jun 2022

Abstract excerpt

BACKGROUND: Alzheimer's disease (AD) is a chronic neurodegenerative disease and the most common form of dementia, especially in the elderly. Due to the increase in life expectancy, in recent years, there has been an excessive growth in the number of people affected by this disease, causing serious problems for health systems. In recent years, research has been intensified to find new therapeutic approaches that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 14-3-3 protein interactions
Share to Down syndrome and intellectual disability research
Share to Genetics and Neurodevelopmental Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35726411
DOI: 10.2174/0929867329666220620162018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's DiseasePMID 35726411Read ↗

Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer’s?Semantic proximity Read ↗

Discovering a novel dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and its impact on tau phosphorylation and amyloid-β formationSemantic proximity Read ↗

The Omnipresence of DYRK1A in Human DiseasesSemantic proximity Read ↗

Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down SyndromeSemantic proximity Read ↗

DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down SyndromeSemantic proximity Read ↗

Aristolactam BIII, a naturally derived DYRK1A inhibitor, rescues Down syndrome-related phenotypes.Semantic proximity Read ↗

DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspectiveSemantic proximity Read ↗

The role of DYRK1A in neurodegenerative diseasesSemantic proximity Read ↗

Down syndrome and DYRK1A overexpression: relationships and future therapeutic directionsSemantic proximity Read ↗

DYRK1A Kinase Inhibitors with Emphasis on CancerSemantic proximity Read ↗

DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down SyndromeSemantic proximity Read ↗

DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.